Quidel Stock Price, News & Analysis

QuidelOrtho (NASDAQ: QDEL), a global provider of in vitro diagnostic technologies, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Investors can access the webcast through QuidelOrtho's investor relations website, or join via phone using specific dial-in numbers. Presentation materials will be available on the company's website concurrent with the call.

QuidelOrtho (NASDAQ: QDEL) has announced a featured session at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) meeting, focusing on Six Sigma metrics in laboratory performance. The session, titled "Real Labs, Real Decisions with Actionable Six Sigma Metrics," will take place on July 29, 2025 at the McCormick Convention Center in Chicago.

The panel discussion will feature experts including Dr. Jared Jaeger as moderator, along with distinguished professionals from the University of Florida PathLab, St. Peter's University Hospital, and UHS Hospitals. The session will explore how QuidelOrtho's Six Sigma tools and real-world laboratory data can be utilized to enhance quality outcomes in clinical settings.

QuidelOrtho (NASDAQ: QDEL) and BÜHLMANN Laboratories AG have announced the integration of two key diagnostic assays on VITROS Systems: the fCAL turbo for inflammatory bowel disease (IBD) detection and fPELA turbo for pancreatic insufficiency diagnosis.

The assays feature rapid results delivery in under 10 minutes, wide reportable ranges, and 90-day analyzer stability. Both tests utilize BÜHLMANN's innovative CALEX Cap technology for simplified sample extraction and are available on VITROS XT 7600, 5600 Integrated System, and 4600 Chemistry Systems.

This partnership aims to enhance non-invasive diagnostic capabilities while reducing healthcare costs and the need for invasive procedures in gastrointestinal and pancreatic health diagnostics.

QuidelOrtho (NASDAQ: QDEL), a global in vitro diagnostics provider, has strengthened its leadership team with two key appointments. Devon Burek joins as Senior Vice President of Global Quality, bringing over 20 years of experience from Roche, while Sergio Gadaleta becomes Senior Vice President of Clinical and Regulatory Affairs, leveraging his experience from BD, 3M, Johnson & Johnson, and the FDA.

Burek will focus on streamlining global quality approaches and enhancing operational effectiveness. Gadaleta, who holds a PhD in chemistry, will lead the company's global clinical trial strategy and regulatory submissions, working closely with the FDA and global health agencies.

QuidelOrtho (QDEL) announced a strategic shift in its molecular diagnostics business, planning to acquire LEX Diagnostics for approximately $100 million upon FDA clearance while discontinuing its Savanna platform development. LEX Diagnostics' innovative platform delivers rapid molecular test results, with positive results for Flu A, Flu B, and COVID-19 in about 6 minutes and negative results in 10 minutes. The company expects FDA 510(k) clearance in late 2025 or early 2026. This strategic decision follows QuidelOrtho's comprehensive review under CEO Brian J. Blaser to drive shareholder value. The company maintains its fiscal 2025 financial guidance previously announced on February 12, 2025.

QuidelOrtho (NASDAQ: QDEL), a provider of in vitro diagnostic technologies, announced its participation in two upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 4 at 9:00 a.m. ET, followed by a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 8:45 a.m. ET. Interested investors can access live webcasts and replays of both events through QuidelOrtho's investor relations website.

QuidelOrtho (QDEL) reported Q1 2025 financial results with total revenue of $693 million, showing 5% growth as reported and 6% in constant currency, excluding COVID-19 and Donor Screening. The company's Labs revenue grew 5% as reported, while non-respiratory revenue remained flat at $573 million. GAAP operating margin improved significantly from -247% to 5%, and adjusted EBITDA margin increased by 450 basis points to 23%. The company reported a GAAP net loss of $13 million ($0.19 per share), compared to a $1.71 billion loss in the prior year period. Cost-saving initiatives drove improved profitability with GAAP operating expenses decreasing by 9%. QuidelOrtho maintained its full-year 2025 guidance, projecting total revenues of $2.60-$2.81 billion and adjusted EBITDA of $575-$615 million.

QuidelOrtho (Nasdaq: QDEL), a global provider of in-vitro diagnostic technologies, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day to discuss the results.

Investors can access the call through the company's website at ir.quidelortho.com or by phone using the following dial-in numbers:

• Domestic: 833-470-1428
• International: +1 929-526-1599
• Conference ID: 170283

Presentation materials will be available on the company's Investor Relations page during the call, and a replay will be accessible shortly after the event.

QuidelOrtho (Nasdaq: QDEL) has launched the Results Manager™ System, an advanced informatics solution designed for laboratories in community hospitals and point-of-care settings. The system offers key features including:

• Real-time quality monitoring for instruments and assays
• Operational efficiency through auto-verification and simplified rule-writing
• Seamless connectivity with multiple instruments
• Enhanced clinical decision-making capabilities
• Cost-effective deployment with easy installation

The system addresses critical challenges such as rising test volumes, staffing shortages, and increasing complexity while maintaining focus on patient care. Early trial users, including Lab Manager Steve Mulliner from MB Healthcare Services , reported positive feedback on the system's intuitive interface and efficiency improvements. QuidelOrtho is now launching the Results Manager system worldwide, with availability varying by country.